Keywords: enzon, begins, second, ph, ezn-2968, study, danish
Enzon begins second Ph I EZN-2968 study
Article | 12 November 2007
Danish biopharmaceutical firm Santaris Pharma AS says that its US licensee, Enzon Pharmaceuticals, has begun a second open-label, non-randomized Phase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
